Bardet-Biedl Syndrome
Symptoms, Doctors, Treatments, Advances & More

Learn About Bardet-Biedl Syndrome

What is the definition of Bardet-Biedl Syndrome?

Bardet-Biedl syndrome is a disorder that affects many parts of the body. The specific features and the course of this condition can vary greatly among affected individuals.

What are the causes of Bardet-Biedl Syndrome?

Genetic changes that cause disease are called pathogenic variants. Pathogenic variants in at least 26 different genes (often called the BBS genes) cause Bardet-Biedl syndrome. These genes are known or suspected to play important roles in the function of certain types of cilia. Cilia are microscopic projections that stick out from the surface of most cells. Primary cilia are a specific type of cilia that transmit signals from the outside of the cell to the inside. They are necessary for the perception of sensory input (such as sight, hearing, and smell), and they play an important role in cell communication. The proteins produced from the BBS genes are involved in the maintenance and function of primary cilia.

How prevalent is Bardet-Biedl Syndrome?

In most of North America and Europe, Bardet-Biedl syndrome affects 1 in 120,000 to 160,000 newborns. The condition is more common on the island of Newfoundland (off the east coast of Canada) and in certain populations of Kuwait. Bardet-Bieldl syndrome is most common on the Faroe Islands in the North Atlantic Ocean, where it affects 1 in 3,700 newborns.

Is Bardet-Biedl Syndrome an inherited disorder?

Bardet-Biedl syndrome is typically inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a pathogenic variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Who are the top Bardet-Biedl Syndrome Local Doctors?
Elite in Bardet-Biedl Syndrome
Medical Genetics
Elite in Bardet-Biedl Syndrome
Medical Genetics
Referral may be required
2901 86th St, 
Urbandale, IA 
Languages Spoken:
English
Accepting New Patients

Val Sheffield is a Medical Genetics provider practicing medicine in Urbandale, Iowa. Dr. Sheffield is rated as an Elite provider by MediFind in the treatment of Bardet-Biedl Syndrome. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Bardet-Biedl Syndrome, Polydactyly, Ocular Hypertension (OHT), and Retinopathy Pigmentary Mental Retardation. Dr. Sheffield is currently accepting new patients.

Elite in Bardet-Biedl Syndrome
Elite in Bardet-Biedl Syndrome
Referral may be required

Guys And St. Thomas' Hospitals

London, ENG, GB 

Elizabeth Forsythe practices practicing medicine in London, United Kingdom. Ms. Forsythe is rated as an Elite expert by MediFind in the treatment of Bardet-Biedl Syndrome. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Bardet-Biedl Syndrome, Obesity, Metabolic Syndrome, and Alstrom Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Bardet-Biedl Syndrome
Elite in Bardet-Biedl Syndrome
Referral may be required
Strasbourg, FR 

Helene Dollfus practices practicing medicine in Strasbourg, France. Ms. Dollfus is rated as an Elite expert by MediFind in the treatment of Bardet-Biedl Syndrome. She is also highly rated in 29 other conditions, according to our data. Her clinical expertise encompasses Bardet-Biedl Syndrome, Leber Congenital Amaurosis, Polydactyly, Alstrom Syndrome, and Vitrectomy.

What are the latest Bardet-Biedl Syndrome Clinical Trials?
A First-In-Human, Open Label, Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of a Single Dose of AXV-101 in Patients With Bardet-Biedl Syndrome 1 (BBS1) Bi-Allelic Mutations and Retinal Degeneration

Summary: The goal of this first in human study is to evaluate the preliminary safety and tolerability of AXV-101 in participants with BBS1. The main questions it aims to answer are: * Is AXV-101 safe and tolerable to use in participants with BBS1? * To determine the therapeutic dose of AXV-101 in participants with BBS1 * To investigate the concentration of AXV-101 in blood, urine and tears (both eyes) Part...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Real-World Effectiveness, Safety and Patient-reported Outcomes of Setmelanotide in Patients With Bardet-Biedl Syndrome: A Prospective Mono Centric Observational Interventional Study

Summary: Bardet-Biedl syndrome (BBS) and other rare disorders associated with impairment of the melanocortin-4 receptor (MC4R) pathway are characterized by severe early-onset obesity, hyperphagia, and substantial morbidity. Setmelanotide, an MC4R agonist, is approved in Europe for selected genetic obesity disorders and reimbursed in Germany for eligible patients. This study aims to evaluate the effectivene...

Who are the sources who wrote this article ?

Published Date: August 25, 2026
Published By: National Institutes of Health